Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5831525 | 0.80 | SLC6A2 (0.44) | SLC6A4SLC6A3SMN1; SMN2SLC6A2 | |
| Hydrochloric Acid SCHEMBL8070333 | 0.73 | SLC9A1 (0.43) | SLC6A3 | |
| SCHEMBL10884180 | 0.73 | EPAS1 (0.46) | ALOX5APFEN1KIF11EPAS1PTGS1 | |
| SCHEMBL4637544 | 0.72 | EPAS1 (0.55) | EPAS1PTGS1NR1H2NR1H3BRD4 | |
| SCHEMBL653313 | 0.71 | PTPN1 (0.48) | SLC6A4SLC6A3SMN1; SMN2EPAS1 | |
| SCHEMBL4637515 | 0.71 | EPAS1 (0.45) | SLC6A4ALOX5APFEN1SMN1; SMN2KIF11 | |
| SCHEMBL586124 | 0.70 | PTGDR2 (0.47) | KCNQ3KCNQ2PTGS2 | |
| SCHEMBL2067362 | 0.70 | NR3C1 (0.50) | KCNQ3KCNQ2EPAS1PTGS2 | |
| SCHEMBL2065914 | 0.70 | PTGDR2 (0.49) | EPAS1 | |
| SCHEMBL1460007 | 0.69 | KIF11 (0.45) | ALOX5APFEN1SMN1; SMN2KIF11EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-20020165234-A1 | Selective B3 adrenergic agonists | CROWELL THOMAS A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-0827746-B1 | Carbazole analogues as selective beta3 adrenergic agonists | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0827746-A1 | Carbazole analogues as selective B3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | SLC6A4 834/4885ALOX5AP 2009/4885FEN1 4768/4885 |
| US-20020165234-A1 | Selective B3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | SLC6A4 467/4885ALOX5AP 1733/4885FEN1 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.